

Artificial Intelligence and Its Transformative Role in Rehabilitation and Pharmaceutical Sciences

Authors:

Rahul Sharma¹, Arun Banik², Vivek Kumar Jha³, Gaurav Agarwal^{4*}, Vinay Kumar Singhal⁵

¹Professor & Principal, Department of Pharmaceutics, Gateway College of Pharmacy, Sonipat, Haryana, India.

²Professor (Speech Pathology and Audiology), Department of Audiology and Speech Language Pathology, Faculty of Allied Health Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana, India.

³Professor, Department of Audiology and Speech Language Pathology, Faculty of Allied Health Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana, India.

⁴Professor, PIET, Panipat, Haryana, India.

⁵Principal, Gateway Institute of Engineering & Technology, Sonipat.

Corresponding Author:

Gaurav Agarwal

<https://doi.org/10.5281/zenodo.17265619>

Revised: 14-September-2025, Accepted: 04-October-2025, Online First: 06-October-2025

ABSTRACT:

Artificial intelligence (AI) has emerged as a transformative force in both rehabilitation sciences and pharmaceutical research. By integrating machine learning, computer vision, natural language processing, robotics, and advanced formulation technologies, AI enhances diagnostic precision, personalizes therapy, optimizes drug design, and strengthens patient engagement. In rehabilitation, these innovations drive progress in occupational therapy, physical therapy, and mental health care through immersive technologies such as virtual reality, robotics, and wearable devices. In pharmaceutical sciences, AI accelerates in silico drug design, supports nanomedicine, and facilitates phytopharmaceutical integration. This review provides a comprehensive account of contemporary advancements, emphasizing the synergistic impact of AI in physical, mental, and pharmacological rehabilitation, while underscoring the convergence of computational tools, novel drug delivery, and holistic patient-centered care.

Keywords: *Artificial intelligence, Machine learning, Computer vision, Occupational therapy, Rehabilitation, Nanomedicine, Phytopharmaceuticals, Drug delivery.*

1. INTRODUCTION:

Rehabilitation encompasses occupational and physical therapy, focusing on restoring functional, emotional, and social capabilities in patients with illness, injury, or disability. According to the World Health Organization, nearly 15% of the global population experiences disability, ranging from mobility impairments to cognitive dysfunctions. In the United States, over 61 million adults report disabilities, with mobility restrictions most prevalent, while 53 million adults live with mental illness. These figures highlight the essential role of rehabilitation in promoting independence, self-esteem, and quality of life.[1]

Rehabilitation relies on interdisciplinary collaboration, where occupational therapy facilitates engagement in daily tasks through adaptive strategies, and physical

therapy restores strength, balance, and mobility. With the advent of AI and digital health technologies virtual reality, mobile health, telemedicine, and wearables rehabilitation practices have evolved toward real-time, data-driven, and patient-centered approaches. Similarly, pharmaceutical sciences face rising demands for precision therapies, where AI supports drug discovery, formulation design, and targeted delivery. Thus, integrating AI into both domains accelerates progress toward holistic care.[2]


2. Artificial Intelligence in Healthcare:

AI provides clinicians with actionable insights by analyzing vast datasets derived from medical records, imaging, laboratory tests, and wearable devices. It supports earlier diagnosis, personalized treatment

strategies, and improved monitoring. In rehabilitation, AI strengthens occupational and physical therapy through data-driven assessments, targeted interventions, and continuous evaluation systems. In pharmaceutical sciences, AI enables rational drug design, optimization of delivery systems, and predictive modeling of clinical

outcomes. Together, these advancements enhance efficiency, reduce healthcare costs, and elevate patient experiences.[3]

Figure 1: Transformative Role of AI In Rehabilitation And Pharmaceutical Sciences.



3. AI in Occupational and Physical Therapy:

3.1 AI-Driven Assessment Tools:

Computer vision and natural language processing (NLP) are core AI applications in therapy. Motion capture systems such as Vicon and Microsoft Kinect track gait and joint movements in conditions like stroke and cerebral palsy, offering objective assessment of mobility. NLP platforms like LanguageLab analyze patient speech, detect impairments, and recommend personalized interventions in aphasia or dementia. These technologies improve diagnostic accuracy and provide real-time data to inform individualized care plans.[4]

3.2 AI-Based Intervention Strategies:

Virtual reality (VR) simulations immerse patients in controlled environments to practice motor and cognitive tasks, enhancing repetition, motivation, and recovery. VR has proven effective in stroke rehabilitation and PTSD therapy. Robotics including exoskeletons, haptic devices, and social robots like Paro enable consistent, task-specific training and emotional engagement. Integration with gamification sustains motivation, particularly for long-term therapy programs.[5]

3.3 Monitoring and Evaluation:

Wearables and machine learning algorithms collect biometric and motion data, supporting remote monitoring and predictive analytics. Devices such as EMG sensors and smartwatches provide continuous feedback, while algorithms like neural networks and random forests assess spasticity, classify performance, and predict rehabilitation outcomes. These systems foster adaptive therapy tailored to individual progress.

4. In Silico Drug Design and Molecular Targeting:

AI-driven in silico methods revolutionize drug discovery by enabling high-throughput screening, virtual docking, and pharmacokinetic prediction. Devgan et al. demonstrated inhibition of the AMF-HER2 complex in trastuzumab-resistant breast cancer through computational modeling [6]. Predictive algorithms refine drug candidates by analyzing toxicity, efficacy, and structural activity relationships [7-9]. Such methods reduce reliance on trial-and-error, accelerating preclinical development and increasing clinical success rates.

5. Novel Formulation Approaches:

Pharmaceutical innovations powered by AI and advanced engineering improve therapeutic delivery and compliance:

- **Sublingual tablets:** Lisinopril formulations bypass first-pass metabolism, enhancing absorption [10].
- **3D-printed tablets:** Personalized pregabalin tablets optimized with QbD provide precise dosing for neuropathic pain [11].
- **Sustained-release systems:** Repaglinide matrix tablets ensure controlled release and adherence in diabetes [12].
- **Semi-herbal nanogels:** Clindamycin-Aloe vera formulations enhance topical delivery and outcomes [13].
- **Microparticles:** Solid lipid microparticles of acyclovir improve antiviral stability [14].
- **Delayed-release tablets:** Montelukast sodium formulations offer targeted respiratory therapy.

These technologies represent the convergence of engineering and medicine, advancing precision therapeutics.

6. Phytopharmaceuticals and Green Innovations:

Phytoconstituents provide antioxidant, anti-inflammatory, and immunomodulatory properties that complement synthetic drugs. Aneja et al. demonstrated phytochemicals' role in psoriasis management [15,16], while Aggarwal et al. reported phyto-nanomedicine's effectiveness in wound healing [17]. Singh and Tushir emphasized standardized extraction for reproducibility [18]. Nutritional interventions such as protein-rich diets and bioflavonoids showed hepatoprotective and nephroprotective benefits [19–21]. Sustainable methods, including green spectrophotometric drug quantification, promote eco-friendly pharmaceutical practices [22].

7. Nanomedicine and Targeted Therapy:

Nanostructured carriers improve therapeutic efficacy in chronic diseases:

- **Neuroendocrine cancers:** Nanocarriers enhanced uptake and delivery [23].
- **Diabetic nephropathy:** Bioflavonoid nanoformulations mitigated renal damage via molecular pathway modulation [24].
- **Immunotherapy:** Monoclonal antibodies remain pivotal in managing type 1 diabetes [25].

Nanotechnology ensures sustained release, reduced toxicity, and site-specific delivery, making it central to modern precision medicine.

8. Artificial Intelligence in Pharmaceutical Research:

AI further accelerates pharmaceutical sciences:

- **Drug discovery:** Syed et al. highlighted AI in predictive modeling and drug repurposing [2].
- **Formulation optimization:** Tablet-in-tablet systems with AI enable staged drug release for cancer therapy.
- **Clinical translation:** AI tools improve diagnostics, treatment planning, and trial efficiency [26].

These applications underscore AI's transformative role in shifting pharmaceutical research toward patient-specific solutions.

9. Clinical and Therapeutic Insights:

AI and advanced formulations must align with healthcare delivery systems to ensure real-world impact:

- Oncology nurses' knowledge enhances pain management translation [27].
- Evidence-based approaches optimize hypertension management in kidney disease [28].
- Analyses of perioperative medication errors strengthen patient safety [29].
- Combination therapies, such as valsartan with hydrochlorothiazide, improve hypertension control [30].

These examples highlight the intersection of technological innovation, clinical expertise, and healthcare infrastructure.

Recent advances in metabolic and medicinal research have highlighted the pivotal roles of dietary components and synthetic derivatives in disease modulation. Otaif et al. [31] emphasized fructose as a major dietary contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes, underlining the metabolic burden of excessive sugar intake and its potential as a target for nutritional and pharmacological interventions. In parallel, Kumar et al. [32] reviewed the medicinal potential of novel imatinib derivatives, illustrating how structural modifications of established tyrosine kinase inhibitors can enhance therapeutic efficacy and overcome resistance in cancer treatment. Furthermore, Sharma et al. [33] explored recent expansions in the antimicrobial profile of quinoline analogues, reflecting ongoing efforts to develop versatile agents capable of combating resistant microbial strains. Collectively, these studies underscore the importance of both nutritional modulation and rational drug design in addressing complex metabolic and infectious diseases, highlighting an integrative approach that spans from dietary influences to advanced medicinal chemistry.

10. Future Perspectives and Conclusion:

AI bridges the gap between pharmaceutical sciences and rehabilitation by fostering personalized, data-driven, and efficient care. Its applications range from robotic therapy for neurological recovery to nanomedicine for targeted cancer therapy. Future directions must prioritize integration aligning computational drug design, green formulations, phytopharmaceuticals, and AI-driven rehabilitation with clinical translation.

A holistic approach combining physical, mental, and pharmacological rehabilitation will redefine precision medicine, reduce disease burden, and improve global health outcomes. AI stands not merely as a technological tool but as a cornerstone for accessible, individualized, and sustainable healthcare.

REFERENCES:

1. Alshami A. Artificial intelligence in rehabilitation: A narrative review on personalized care, outcome prediction, and real-time patient monitoring. *Science Direct*. 2025.
2. Kandhare P. Artificial intelligence in pharmaceutical sciences: Historical evolution, current applications, and future potential. *Science Direct*. 2025.
3. Wu Y. Artificial intelligence for drug delivery: Yesterday, today, and tomorrow. *ScienceDirect*. 2025.
4. Dipankar P. Artificial intelligence-based advancements in nanomedicine development for brain disorders. *Frontiers in Medicine*. 2025
5. Sridhar D. Artificial intelligence in predicting personalized nanocarrier formulations for phytoconstituents. *Science Direct*. 2025
6. Devgan M, Karar PK, Agarwal G, Mohan A, Gangwar P. In silico designing of drugs for the inhibition of AMF-HER2 complex in trastuzumab resistant breast cancer. *Indian J Biotechnol*. 2016;15(3):292-8.
7. Syed MU, Agarwal G, Agarwal S. An overview of the role of artificial intelligence and machine learning in pharmaceutical research and development. *Lat Am J Pharm*. 2023;42:1-8.
8. Agarwal G, Kumar P, Agarwal S, VSN MD, AN N. Formulation Development and Evaluation of Delayed-release Tablets of Montelukast Sodium. *Asian Journal of Pharmaceutical and Health Sciences*. 2018;8(3)..
9. Khurana S, Malik A, Narwal S, Agarwal G, Sangwan K. Potential of artificial intelligence in healthcare sector. In: *Proc 2024 Int Conf Comput Intell Comput*. 2024.
10. Grover I, Agarwal G. Formulation and evaluation of sublingual tablets of lisinopril. NISCAIR-CSIR, India. 2012.
11. Agarwal G. Formulation and evaluation of 3D printed pregabalin tablets targeted for neuropathic pain by QbD approach for personalized medicine. *Int J Life Sci Pharma Res*. 2022;11(6):1-13.
12. Agarwal G. Formulation & evaluation of sustained release matrix tablet of repaglinide. *Open Access Biostat Bioinforma*. 2018;1(2).
13. Agarwal S, Karar PK, Agarwal G. Semi-herbal nanogel of clindamycin phosphate and Aloe vera: formulation and evaluation. *Modern Applications of Bioequivalence and Bioavailability*. 2017;2(5):1-5.
14. Nagappa AN, Agarwal G, Chikkamath V, Agarwal S, Rani R, Karar PK. Formulation and evaluation of acyclovir sodium solid lipid microparticles. *Am. J. Adv. Drug Deliv*. 2016;4(5):1078-84.
15. Singh PA, Tushir S, Hazra S, Purewal SS, Agarwal G. Novel approaches for the extraction and identification of phytoconstituents from herbs and spices. *The Natural Products Journal*. 2025 May;15(4):E060624230784.
16. Aneja S, Mittal A, Dhiman N, Agarwal G. A review on phytoconstituents for the treatment of psoriasis. *Pharmacogn Rev*. 2023;17(34).
17. Aggarwal D, Kamal CM, Agarwal G, Kumar A, Sharma D. Understanding of phyto-nanomedicine for the management of inflammation and wound healing: an outlook. *Int J Pharm Sci Res*. 2023;14(10):4716-23.
18. Singh PA, Tushir S, Hazra S, Purewal SS, Agarwal G. Novel approaches for the extraction and identification of phytoconstituents from herbs and spices. *Nat Prod J*. 2025;15(4):E060624230784.
19. Xiong Y, Sharma HP, Goyal RK, Narwal S, Berwal A, Jain S, Priya M, et al.

- Bioflavonoid combination attenuates diabetes-induced nephropathy in rats via modulation of MMP-9/TIMP-1, TGF- β , and GLUT-4-associated pathways. *Heliyon*. 2024;10(13).
20. Karar PK, Agarwal G, Agarwal S, Devgan M. Effect of dietary protein against excess vitamin A induced hepatotoxicity in rats. *Am J Adv Drug Deliv*. 2017;5(2):59-63.
 21. Al Khairat M, Otayf AY, Agarwal S, Agarwal G. Dietary and natural aid for alcoholic liver disease steatosis and cirrhosis. *Afr J Bio Sci*. 2024;6:3096-114.
 22. Saiphali K, Al Khairat M, Otayf AY, Agarwal S, Agarwal G. An Approach Towards Green Analytical Chemistry: Spectrophotometric Method for the Determination of Celecoxib in Capsule Formulations. *African Journal of Biological Sciences*. 2024;6(9):1198-212.
 23. Kar A, Agarwal DG, Agarwal DS. A review on nanostructure drug carriers for treatment and management of neuroendocrine cancer. *Int J Pharm Sci*. 2023;14(1):b1-9.
 24. Agarwal G, Patel M. Review on monoclonal antibodies (MAbs) as a therapeutic approach for type 1 diabetes. *Curr Diabetes Rev*. 2024;20(7):23-8.
 25. Agarwal S, Agarwal G, Sharma P. A review on tablet in tablet for cancer and use of artificial intelligence (AI). *J Cancer Res Rev Rep*. 2024;SRC/JCRR-214.
 26. Agarwal G, Agarwal S, Sharma P, Khan S. Enhancing cancer treatment prognosis through AI-driven immunotherapy predictions. *Curr Cancer Ther Rev*. 2025.
 27. Baalann KP, Joseph D, Bhandari A, Kulkarni P, Agarwal G, Agarwal S. Oncology nurses' knowledge, attitudes, and factors in cancer pain – a systematic review. *Malays J Nurs*. 2024;15(4):196-212.
 28. Ghouse Z, Patel M, Agarwal S, Singhal R, Agarwal G. Understanding emerging trends in the management of hypertension in chronic kidney disease: a systematic review. *Eur Chem Bull*. 2023;12(4):2970-81.
 29. Agarwal G. Perioperative medication errors: review on cause, consequences and prevention. *Int J Pharma Bio Sci*. 2021;12(2):136-42.
 30. Agarwal G. Role of combination therapy (valsartan plus hydrochlorothiazide) in hypertension: a review. *Eur J Biomed Pharm Sci*. 2016;3(1):137-40.
 31. Otayf AY, Agarwal G, Al Khairat M, Khormi EA, Alnemi H, Alhazmi A, et al. Fructose, the sweet culprit behind nonalcoholic fatty liver disease and type 2 diabetes. *Curr Diabetes Rev*. 2025.
 32. Kumar S, Agarwal G, Sangwan K. A review on medicinal approaches of novel imatinib derivatives. *Current Topics in Medicinal Chemistry*. 2025 May;25(12):1492-516.
 33. Sharma K, Sanduja M, Kumar A, Singh M, Sharma A, Yadav R, Dahiya R, Agarwal G, Narwal S. Recent Expansions in Anti-Microbial Profile of Quinoline Analogues: A Review. *Current Organic Chemistry*. 2025.